Activation of farnesoid X receptor upregulates binding immunoglobulin protein expression and alleviates diabetic nephropathy

Figure 1 Farnesoid X receptor positively regulates its expression by binding to the binding immunoglobulin protein promoter region. A: Fluorescent enzyme reporter gene detection showed that the activity of the binding immunoglobulin protein (BiP) gene promoter increased in a dose-dependent manner after treatment with farnesoid X receptor agonist obeticholic acid (INT-747); B: After truncating the BiP gene promoter sequence, luciferase reporter gene detection showed that transcriptional activity was still present in the -376 to +200 sequence of the BiP gene promoter; C: Chromatin immunoprecipitation quantitative real time polymerase chain reaction results show that anti farnesoid X receptor antibodies significantly enrich the promoter sequence of BiP gene. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. HG: High glucose; DMSO: Dimethyl sulfoxide; INT-747: Obeticholic acid; FXR: Farnesoid X receptor; Luc: Luciferase.